Contrave Approval Status
- FDA approved: No
- Brand name: Contrave
- Generic name: bupropion and naltrexone
- Company: Orexigen Therapeutics, Inc.
- Treatment for: Obesity
Contrave (bupropion SR/naltrexone SR) is an investigational combination therapy believed to address both behavioral and physiological drivers of obesity.
FDA Approval Status for Contrave
|Dec 11, 2013||Orexigen Resubmits Contrave New Drug Application|
|Sep 20, 2011||Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave|
|Jun 23, 2011||Obesity Groups See Evidence FDA Decisions Will Discourage Obesity Research|
|Jun 3, 2011||Orexigen Therapeutics Provides a Regulatory Update on Contrave NDA|
|Feb 4, 2011||Obesity Society Disappointed by FDA Delay on Approval of Obesity Drug|
|Feb 1, 2011||FDA Issues Complete Response to New Drug Application for Contrave for the Management of Obesity|
|Dec 8, 2010||Orexigen Therapeutics' Investigational Drug Contrave Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity|
|Jun 24, 2010||Orexigen Therapeutics Announces Date of FDA Advisory Committee Review of Contrave for the Treatment of Obesity|
|Jun 15, 2010||Orexigen Therapeutics Announces FDA Acceptance of Contrave New Drug Application for the Treatment of Obesity|
|Mar 31, 2010||Orexigen Therapeutics Submits Contrave New Drug Application to FDA for the Treatment of Obesity|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.